Login to Your Account

Clinic Roundup

Thursday, March 29, 2012
• Navidea Biopharmaceuticals Inc. (formerly Neoprobe Corp.), of Dublin, Ohio, said data from its Phase III study of Lymphoseek (99m-Tc-Tilmanocept) in oral and squamous cell cancers suggested the radiopharmaceutical improves identification of primary draining nodes to properly stage patients with head and neck squamous cell cancers using sentinel lymph node mapping.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription